\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ and\\ laboratory\\:\\ \ \(0\)\
\-\ pleural\\ effusion\\ has\\ a\\ high\\ lipid\\ content\ \(0\)\
\-\ treatment\\ and\\ follow\\-up\\:\\ \ \(0\)\
\-\ treatment\\ includes\\ oxygen\\ therapy\\,\\ medical\\ or\\ surgical\\ pleurodesis\\,\\ and\\ estrogen\\ lowering\\ therapies\\.\\ \\ most\\ commonly\\,\\ patients\\ will\\ receive\\ a\\ bilateral\\ oophorectomy\\;\\ otherwise\\,\\ depot\\ progesterone\\,\\ tamoxifen\\,\\ or\\ lhrh\\ analogs\\ may\\ be\\ used\\.\\ \\ currently\\,\\ a\\ trial\\ using\\ rapamycin\\ which\\ inhibits\\ tuberin\\ formation\\ is\\ being\\ studied\\ for\\ lam\\ and\\ tuberous\\ sclerosis\\.\\ \\ in\\ end\\-stage\\ lung\\ disease\\,\\ lung\\ transplantation\\ becomes\\ necessary\\ for\\ survival\\.\\ \\ in\\ a\\ few\\ rare\\ instances\\,\\ allograft\\ lungs\\ have\\ succumbed\\ to\\ lam\\ through\\ hematogenous\\ spread\\.\ \(0\)\
\-\ patients\\ with\\ lam\\ are\\ advised\\ not\\ to\\ fly\\ or\\ travel\\ to\\ areas\\ of\\ high\\ altitude\\ to\\ reduce\\ the\\ risk\\ of\\ pneumothoraces\\.\\ \\ they\\ are\\ discouraged\\ from\\ becoming\\ pregnant\\ as\\ this\\ can\\ lead\\ to\\ a\\ high\\ estrogen\\ state\\ that\\ accelerates\\ disease\\.\ \(0\)\
\-\ image\\ findings\\:\\ \ \(0\)\
\-\ cxr\\:\\ \\ this\\ patient\\ has\\ a\\ large\\,\\ dense\\ pleural\\ effusion\\ in\\ right\\ lower\\ lobe\\ and\\ a\\ bilaterally\\ diffuse\\ mild\\ linear\\ reticular\\ pattern\\.\ \(0\)\
\-\ ct\\:\\ \\ this\\ patient\\ has\\ cystic\\ air\\ pockets\\ throughout\\ all\\ lung\\ fields\\ and\\ a\\ dense\\ pleural\\ effusion\\ in\\ the\\ right\\ lower\\ lobe\\.\ \(0\)\
\-\ pulmonary\\ lymphangioleiomyomatosis\\ \\(lam\\)\ \(0\)\
\-\ differential\\ diagnosis\\ for\\ these\\ findings\\ in\\ this\\ case\\:\ \(0\)\
\-\ pulmonary\\ lymphangioleiomyomatosis\\,\\ tuberous\\ sclerosis\\,\\ eosinophilic\\ granuloma\\ \\(langerhans\\ histiocytosis\\)\\,\\ emphysema\\,\\ cystic\\ fibrosis\\,\\ bronchiectasis\\,\\ idiopathic\\ pulmonary\\ fibrosis\\,\\ neurofibromatosis\\ \\(types\\ 1\\ and\\ 2\\)\\,\\ metastatic\\ leiomyosarcoma\\,\\ metastatic\\ leiomyoma\\,\\ metastatic\\ endometrial\\ stromal\\ tumor\\,\\ diffuse\\ pulmonary\\ lymphangiomatosis\ \(0\)\
\-\ history\\ \\(can\\ include\\ gestational\\ age\\,\\ or\\ age\\ in\\ days\\,\\ weeks\\,\\ months\\)\\:\ \(0\)\
\-\ 48\\ year\\-old\\ female\\ with\\ history\\ of\\ lung\\ disease\\ with\\ recurrent\\ pneumothoraces\ \(1\)\
\-\ though\\ not\\ given\\ in\\ this\\ case\\,\\ symptoms\\ of\\ dyspnea\\ and\\ cough\\ are\\ most\\ common\\.\\ \\ others\\ include\\ hemoptysis\\ and\\ chest\\ pain\\.\ \(0\)\
\-\ discussion\\ \\(include\\ references\\)\\:\\ \ \(0\)\
\-\ this\\ rare\\ disease\\ occurs\\ in\\ women\\ of\\ childbearing\\ age\\,\\ mostly\\ caucasians\\.\\ \\ it\\ is\\ caused\\ by\\ proliferating\\ smooth\\ muscle\\ in\\ the\\ interstitium\\.\\ \\ although\\ not\\ cancerous\\,\\ it\\ can\\ metastasize\\ to\\ other\\ parts\\ of\\ the\\ body\\.\\ \\ it\\ is\\ estimated\\ that\\ there\\ may\\ be\\ a\\ 1\\,000\\ women\\ with\\ this\\ disease\\ in\\ the\\ united\\ states\\.\\ \\ the\\ nih\\ follows\\ the\\,\\ approximately\\,\\ 350\\ known\\ patients\\.\\ \\ many\\ patients\\ are\\ misdiagnosed\\ with\\ asthma\\ or\\ copd\\.\ \(0\)\
\-\ though\\ idiopathic\\,\\ it\\ is\\ closely\\ related\\ to\\ tuberous\\ sclerosis\\.\\ \\ in\\ fact\\,\\ some\\ believe\\ that\\ it\\ may\\ possibly\\ be\\ an\\ attenuated\\ or\\ mosaic\\ presentation\\ of\\ tuberous\\ sclerosis\\.\\ \\ unlike\\ tuberous\\ sclerosis\\,\\ there\\ are\\ no\\ brain\\ or\\ skin\\ lesions\\.\\ \\ the\\ progression\\ of\\ disease\\ has\\ been\\ clinically\\ linked\\ to\\ estrogen\\ levels\\.\ \(0\)\
\-\ complications\\ include\\ spontaneous\\ pneumothraces\\ \\(50\\%\\)\\,\\ which\\ may\\ be\\ bilateral\\ or\\ recurrent\\,\\ renal\\ angiomyolipomas\\ \\(hamartomas\\,\\ 50\\%\\)\\,\\ hematothorax\\,\\ chylothorax\\,\\ chyloperitoneum\\,\\ chylouria\\,\\ and\\ chylopericardium\\.\ \(0\)\
\-\ classically\\,\\ lam\\ entails\\ a\\ 8\\-10\\ year\\ survival\\ rate\\,\\ but\\ patients\\ may\\ now\\ live\\ for\\ 20\\-50\\ more\\ years\\ with\\ treatment\\.\ \(0\)\
\-\ \\â\\€\\¢discussion\\ with\\ dr\\.\\ avila\\ of\\ the\\ nih\\.\ \(0\)\
\-\ \\â\\€\\¢kazuhiro\\ matsui\\,\\ et\\ al\\,\\ prognostic\\ significance\\ of\\ pulmonary\\ lymphangioleiomyomatosis\\ histologic\\ score\\,\\ am\\ j\\ surg\\ pathol\\ 2001\\;25\\:479\\-484\\.\ \(0\)\
\-\ \\â\\€\\¢kumasaka\\ t\\,\\ etal\\,\\ lymphangiogenesis\\ in\\ lymphangioleiomyomatosis\\:\\ its\\ implication\\ in\\ the\\ progression\\ of\\ lymphangioleiomyomatosis\\,\\ am\\ j\\ surg\\ pathol\\.\\ 2004\\ aug\\;28\\(8\\)\\:1007\\-1016\\.\\ \ \(0\)\
\-\ \\â\\€\\¢uptodate\\ online\\:\\ \\ pulmonary\\ lymphangioleiomyomatosis\ \(0\)\
\-\ \\â\\€\\¢http\\:\\/\\/lam\\.uc\\.edu\\/html\\/disease\\.html\\ \\(lam\\ foundation\\)\\.\ \(0\)\
\-\ \\â\\€\\¢http\\:\\/\\/www\\.lungusa\\.org\\/site\\/pp\\.asp\\?c\\=dvluk9o0e\\&b\\=36\\ \\(am\\.\\ lung\\ as\\.\\)\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lam\\:\\ 0\\.06459807932835201\ \(0\)\
\-\ lymphangioleiomyomatosis\\:\\ 0\\.0630251132076657\ \(0\)\
\-\ tuberous\\:\\ 0\\.04000548095062234\ \(0\)\
\-\ estrogen\\:\\ 0\\.03229903966417601\ \(0\)\
\-\ \\â\\€\\¢http\\:\\ 0\\.027627113072811404\ \(0\)\
\-\ sclerosis\\:\\ 0\\.02609961933185668\ \(0\)\
\-\ pulmonary\\:\\ 0\\.02547500316551085\ \(0\)\
\-\ \\:\\:\\ 0\\.023066832979401326\ \(0\)\
\-\ pneumothoraces\\:\\ 0\\.02251120355996693\ \(0\)\
\-\ pathol\\:\\ 0\\.02251120355996693\ \(0\)\
\-\ am\\:\\ 0\\.02243202967433622\ \(0\)\
\-\ nih\\:\\ 0\\.022152834459089974\ \(0\)\
\-\ \\,\\:\\ 0\\.02209878085855407\ \(0\)\
\-\ lung\\:\\ 0\\.021047271430601585\ \(0\)\
\-\ patients\\:\\ 0\\.0188059064571941\ \(0\)\
\-\ surg\\:\\ 0\\.01735355903830677\ \(0\)\
\-\ pleural\\:\\ 0\\.01693035815649641\ \(0\)\
\-\ effusion\\:\\ 0\\.016567213878598986\ \(0\)\
\-\ it\\:\\ 0\\.016333744766437217\ \(0\)\
\-\ include\\:\\ 0\\.016307166585240045\ \(0\)\
\-\ may\\:\\ 0\\.01593816640219493\ \(0\)\
\-\ survival\\:\\ 0\\.015583033739351151\ \(0\)\
\-\ depot\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ lhrh\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ rapamycin\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ pneumothraces\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ hematothorax\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ chylouria\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ chylopericardium\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ \\â\\€\\¢discussion\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ avila\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ \\â\\€\\¢kazuhiro\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ matsui\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ 25\\:479\\-484\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ \\â\\€\\¢kumasaka\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ etal\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ lymphangiogenesis\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ \\:1007\\-1016\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ \\â\\€\\¢uptodate\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ \\/\\/lam\\.uc\\.edu\\/html\\/disease\\.html\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ \\/\\/www\\.lungusa\\.org\\/site\\/pp\\.asp\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ c\\=dvluk9o0e\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ b\\=36\\:\\ 0\\.014992378272051868\ \(0\)\
\-\ progression\\:\\ 0\\.014459762695573681\ \(0\)\
\-\ disease\\:\\ 0\\.014252423889956164\ \(0\)\
\-\ women\\:\\ 0\\.014122718809028679\ \(0\)\
\-\ tuberin\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ discouraged\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ accelerates\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ lymphangiomatosis\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ caucasians\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ proliferating\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ chyloperitoneum\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ implication\\:\\ 0\\.013813556536405702\ \(0\)\
\-\ dense\\:\\ 0\\.013729234458690369\ \(0\)\
\-\ or\\:\\ 0\\.01362615984984636\ \(0\)\
\-\ though\\:\\ 0\\.013481252245057418\ \(0\)\
\-\ age\\:\\ 0\\.013269950640532175\ \(0\)\
\-\ idiopathic\\:\\ 0\\.013250127544688343\ \(0\)\
\-\ j\\:\\ 0\\.013128201926412371\ \(0\)\
\-\ altitude\\:\\ 0\\.013123990026017667\ \(0\)\
\-\ mosaic\\:\\ 0\\.013123990026017667\ \(0\)\
\-\ entails\\:\\ 0\\.013123990026017667\ \(0\)\
\-\ fibrosis\\:\\ 0\\.012941779353300143\ \(0\)\
\-\ pleurodesis\\:\\ 0\\.012634734800759537\ \(0\)\
\-\ analogs\\:\\ 0\\.012634734800759537\ \(0\)\
\-\ fly\\:\\ 0\\.012634734800759537\ \(0\)\
\-\ misdiagnosed\\:\\ 0\\.012634734800759537\ \(0\)\
\-\ \\(\\:\\ 0\\.012285063371494228\ \(0\)\
\-\ recurrent\\:\\ 0\\.012265415888180534\ \(0\)\
\-\ lowering\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ succumbed\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ pockets\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ cancerous\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ 350\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ chylothorax\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ foundation\\:\\ 0\\.012255238965191153\ \(0\)\
\-\ \\)\\:\\ 0\\.01213499476383172\ \(0\)\
\-\ 1\\,000\\:\\ 0\\.011945168290371502\ \(0\)\
\-\ high\\:\\ 0\\.011931357454473547\ \(0\)\
\-\ oophorectomy\\:\\ 0\\.011683007270257117\ \(0\)\
\-\ inhibits\\:\\ 0\\.011683007270257117\ \(0\)\
\-\ studied\\:\\ 0\\.011683007270257117\ \(0\)\
\-\ allograft\\:\\ 0\\.011683007270257117\ \(0\)\
\-\ childbearing\\:\\ 0\\.011683007270257117\ \(0\)\
\-\ progesterone\\:\\ 0\\.011455913065113371\ \(0\)\
\-\ 8\\-10\\:\\ 0\\.011455913065113371\ \(0\)\
\-\ 20\\-50\\:\\ 0\\.011455913065113371\ \(0\)\
\-\ online\\:\\ 0\\.011455913065113371\ \(0\)\
\-\ this\\:\\ 0\\.011442109682311108\ \(0\)\
\-\ rare\\:\\ 0\\.011286905437664273\ \(0\)\
\-\ tamoxifen\\:\\ 0\\.011255601779983465\ \(0\)\
\-\ aug\\:\\ 0\\.011255601779983465\ \(0\)\
\-\ 50\\:\\ 0\\.011057816383142191\ \(0\)\
\-\ metastatic\\:\\ 0\\.010975047977633113\ \(0\)\
\-\ has\\:\\ 0\\.010916326329893047\ \(0\)\
\-\ instances\\:\\ 0\\.010630219500858778\ \(0\)\
\-\ attenuated\\:\\ 0\\.010630219500858778\ \(0\)\
\-\ interstitium\\:\\ 0\\.010504185534610952\ \(0\)\
\-\ believe\\:\\ 0\\.010504185534610952\ \(0\)\
\-\ live\\:\\ 0\\.010504185534610952\ \(0\)\
\-\ end\\-stage\\:\\ 0\\.010386850719156952\ \(0\)\
\-\ angiomyolipomas\\:\\ 0\\.010386850719156952\ \(0\)\
\-\ hamartomas\\:\\ 0\\.010386850719156952\ \(0\)\
\-\ \\;\\:\\ 0\\.010333781573737722\ \(0\)\
\-\ metastasize\\:\\ 0\\.010277091329467206\ \(0\)\
\-\ becoming\\:\\ 0\\.010173988231139935\ \(0\)\
\-\ parts\\:\\ 0\\.010076780044337302\ \(0\)\
\-\ travel\\:\\ 0\\.0099848289877552\ \(0\)\
\-\ are\\:\\ 0\\.009905390072530627\ \(0\)\
\-\ lipid\\:\\ 0\\.009897595493898821\ \(0\)\
\-\ can\\:\\ 0\\.00988888955341362\ \(0\)\
\-\ content\\:\\ 0\\.009814619024222915\ \(0\)\
\-\ therapies\\:\\ 0\\.009735503351374459\ \(0\)\
\-\ dr\\:\\ 0\\.009735503351374459\ \(0\)\
\-\ prognostic\\:\\ 0\\.009735503351374459\ \(0\)\
\-\ transplantation\\:\\ 0\\.009659905115709777\ \(0\)\
\-\ leiomyosarcoma\\:\\ 0\\.009587524819079169\ \(0\)\
\-\ linked\\:\\ 0\\.009587524819079169\ \(0\)\
\-\ reticular\\:\\ 0\\.009451397765212612\ \(0\)\
\-\ hematogenous\\:\\ 0\\.009387213533949267\ \(0\)\
\-\ score\\:\\ 0\\.009387213533949267\ \(0\)\
\-\ in\\:\\ 0\\.009316605428270942\ \(0\)\
\-\ significance\\:\\ 0\\.009265684683639495\ \(0\)\
\-\ histologic\\:\\ 0\\.009208028983510787\ \(0\)\
\-\ trial\\:\\ 0\\.009152263978709782\ \(0\)\
\-\ advised\\:\\ 0\\.009152263978709782\ \(0\)\
\-\ unlike\\:\\ 0\\.009152263978709782\ \(0\)\
\-\ stromal\\:\\ 0\\.009045936840986424\ \(0\)\
\-\ be\\:\\ 0\\.008964331451319245\ \(0\)\
\-\ united\\:\\ 0\\.008945867963396402\ \(0\)\
\-\ treatment\\:\\ 0\\.008824576324494321\ \(0\)\
\-\ diffuse\\:\\ 0\\.008799344967262975\ \(0\)\
\-\ closely\\:\\ 0\\.008761831254824578\ \(0\)\
\-\ copd\\:\\ 0\\.008718773758252656\ \(0\)\
\-\ langerhans\\:\\ 0\\.008595779435838325\ \(0\)\
\-\ receive\\:\\ 0\\.008556681615728293\ \(0\)\
\-\ pregnant\\:\\ 0\\.008556681615728293\ \(0\)\
\-\ leiomyoma\\:\\ 0\\.008556681615728293\ \(0\)\
\-\ others\\:\\ 0\\.008556681615728293\ \(0\)\
\-\ bronchiectasis\\:\\ 0\\.008481083380063611\ \(0\)\
\-\ mostly\\:\\ 0\\.008481083380063611\ \(0\)\
\-\ classically\\:\\ 0\\.008481083380063611\ \(0\)\
\-\ estimated\\:\\ 0\\.008408703083433005\ \(0\)\
\-\ cystic\\:\\ 0\\.008383104446434551\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.008373636268462365\ \(0\)\
\-\ oxygen\\:\\ 0\\.008339277922684272\ \(0\)\
\-\ endometrial\\:\\ 0\\.008240181140160504\ \(0\)\
\-\ reduce\\:\\ 0\\.008208391798303101\ \(0\)\
\-\ state\\:\\ 0\\.008208391798303101\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.008086862947993332\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.008029207247864621\ \(0\)\
\-\ asthma\\:\\ 0\\.008029207247864621\ \(0\)\
\-\ emphysema\\:\\ 0\\.007946230778188717\ \(0\)\
\-\ fields\\:\\ 0\\.007919447858174875\ \(0\)\
\-\ lobe\\:\\ 0\\.007820834516746714\ \(0\)\
\-\ follows\\:\\ 0\\.007816344759847604\ \(0\)\
\-\ 2004\\:\\ 0\\.007816344759847604\ \(0\)\
\-\ eosinophilic\\:\\ 0\\.0077915168696755755\ \(0\)\
\-\ gestational\\:\\ 0\\.007742922698852351\ \(0\)\
\-\ 2001\\:\\ 0\\.0077191365730449706\ \(0\)\
\-\ fact\\:\\ 0\\.007649711412296238\ \(0\)\
\-\ becomes\\:\\ 0\\.007604954085225874\ \(0\)\
\-\ that\\:\\ 0\\.007530513921218486\ \(0\)\
\-\ possibly\\:\\ 0\\.00743684892427922\ \(0\)\
\-\ types\\:\\ 0\\.0074169577001921595\ \(0\)\
\-\ granuloma\\:\\ 0\\.007143533855655168\ \(0\)\
\-\ 48\\:\\ 0\\.007110186115198746\ \(0\)\
\-\ bilateral\\:\\ 0\\.007053801800389265\ \(0\)\
\-\ spread\\:\\ 0\\.007029570062656936\ \(0\)\
\-\ lead\\:\\ 0\\.0069677203276724544\ \(0\)\
\-\ dyspnea\\:\\ 0\\.006878969046770125\ \(0\)\
\-\ 28\\:\\ 0\\.0068503855122184565\ \(0\)\
\-\ states\\:\\ 0\\.006836271901989382\ \(0\)\
\-\ discussion\\:\\ 0\\.006808391273119184\ \(0\)\
\-\ spontaneous\\:\\ 0\\.006780960351469723\ \(0\)\
\-\ \\%\\:\\ 0\\.006780003514782339\ \(0\)\
\-\ a\\:\\ 0\\.006744894588751723\ \(0\)\
\-\ t\\:\\ 0\\.006727391189804126\ \(0\)\
\-\ most\\:\\ 0\\.006710323611319987\ \(0\)\
\-\ few\\:\\ 0\\.006540314837398805\ \(0\)\
\-\ lower\\:\\ 0\\.006536945814162798\ \(0\)\
\-\ necessary\\:\\ 0\\.006437211739071535\ \(0\)\
\-\ clinically\\:\\ 0\\.006371792894126304\ \(0\)\
\-\ smooth\\:\\ 0\\.006361130286960325\ \(0\)\
\-\ case\\:\\ 0\\.006358858615194798\ \(0\)\
\-\ using\\:\\ 0\\.00630879753412571\ \(0\)\
\-\ not\\:\\ 0\\.006300095263989466\ \(0\)\
\-\ findings\\:\\ 0\\.006186520189761767\ \(0\)\
\-\ linear\\:\\ 0\\.006160819001830422\ \(0\)\
\-\ al\\:\\ 0\\.006160819001830422\ \(0\)\
\-\ cxr\\:\\ 0\\.006132707944090267\ \(0\)\
\-\ caused\\:\\ 0\\.006095935046108693\ \(0\)\
\-\ references\\:\\ 0\\.0060422248895605655\ \(0\)\
\-\ formation\\:\\ 0\\.00599872685930606\ \(0\)\
\-\ related\\:\\ 0\\.00599872685930606\ \(0\)\
\-\ levels\\:\\ 0\\.00599872685930606\ \(0\)\
\-\ many\\:\\ 0\\.005973152237937793\ \(0\)\
\-\ occurs\\:\\ 0\\.0059647121200090015\ \(0\)\
\-\ et\\:\\ 0\\.005947956513813404\ \(0\)\
\-\ includes\\:\\ 0\\.005858640128977611\ \(0\)\
\-\ to\\:\\ 0\\.005810450455006616\ \(0\)\
\-\ currently\\:\\ 0\\.005758797270428669\ \(0\)\
\-\ complications\\:\\ 0\\.005758797270428669\ \(0\)\
\-\ \\?\\:\\ 0\\.00567156377657229\ \(0\)\
\-\ rate\\:\\ 0\\.00566449233074123\ \(0\)\
\-\ skin\\:\\ 0\\.005581851930678534\ \(0\)\
\-\ used\\:\\ 0\\.005575143124061159\ \(0\)\
\-\ cough\\:\\ 0\\.00556846067824502\ \(0\)\
\-\ pattern\\:\\ 0\\.005555174046039588\ \(0\)\
\-\ lungs\\:\\ 0\\.005503041833299789\ \(0\)\
\-\ commonly\\:\\ 0\\.005483897012679662\ \(0\)\
\-\ its\\:\\ 0\\.005483897012679662\ \(0\)\
\-\ throughout\\:\\ 0\\.005440046473299195\ \(0\)\
\-\ 8\\:\\ 0\\.005433873398383245\ \(0\)\
\-\ which\\:\\ 0\\.005425661861369213\ \(0\)\
\-\ laboratory\\:\\ 0\\.005355598190228003\ \(0\)\
\-\ year\\-old\\:\\ 0\\.005338035070915334\ \(0\)\
\-\ risk\\:\\ 0\\.005263956883263752\ \(0\)\
\-\ they\\:\\ 0\\.005236302936202902\ \(0\)\
\-\ otherwise\\:\\ 0\\.0052199238663713345\ \(0\)\
\-\ muscle\\:\\ 0\\.0052199238663713345\ \(0\)\
\-\ \\&\\:\\ 0\\.0051044011771112785\ \(0\)\
\-\ being\\:\\ 0\\.005064265266667616\ \(0\)\
\-\ presentation\\:\\ 0\\.005005783391991637\ \(0\)\
\-\ given\\:\\ 0\\.004981997266184255\ \(0\)\
\-\ now\\:\\ 0\\.004967883655955183\ \(0\)\
\-\ for\\:\\ 0\\.004959919378521871\ \(0\)\
\-\ air\\:\\ 0\\.004917113310462527\ \(0\)\
\-\ although\\:\\ 0\\.004908042994177898\ \(0\)\
\-\ areas\\:\\ 0\\.0048900462096021545\ \(0\)\
\-\ bilaterally\\:\\ 0\\.004773308228782148\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.0047279540670777925\ \(0\)\
\-\ body\\:\\ 0\\.004719836246069872\ \(0\)\
\-\ differential\\:\\ 0\\.0046138772608043015\ \(0\)\
\-\ known\\:\\ 0\\.004598726334122142\ \(0\)\
\-\ will\\:\\ 0\\.004546736425814867\ \(0\)\
\-\ image\\:\\ 0\\.004539437357648981\ \(0\)\
\-\ approximately\\:\\ 0\\.00449628882067276\ \(0\)\
\-\ medical\\:\\ 0\\.004471615306234701\ \(0\)\
\-\ days\\:\\ 0\\.004454207986687037\ \(0\)\
\-\ some\\:\\ 0\\.004413143288889046\ \(0\)\
\-\ as\\:\\ 0\\.004396522128891591\ \(0\)\
\-\ brain\\:\\ 0\\.00437304680833803\ \(0\)\
\-\ renal\\:\\ 0\\.004366455016085151\ \(0\)\
\-\ there\\:\\ 0\\.004325563117227853\ \(0\)\
\-\ years\\:\\ 0\\.004267420301051841\ \(0\)\
\-\ through\\:\\ 0\\.00412747792248447\ \(0\)\
\-\ weeks\\:\\ 0\\.004124622035546171\ \(0\)\
\-\ all\\:\\ 0\\.004110414097672263\ \(0\)\
\-\ history\\:\\ 0\\.004014335162268991\ \(0\)\
\-\ months\\:\\ 0\\.00396928791613957\ \(0\)\
\-\ been\\:\\ 0\\.003953732805210869\ \(0\)\
\-\ lesions\\:\\ 0\\.0038904090243944687\ \(0\)\
\-\ therapy\\:\\ 0\\.0038854435310214505\ \(0\)\
\-\ mild\\:\\ 0\\.003826961656345471\ \(0\)\
\-\ is\\:\\ 0\\.0038251073359505143\ \(0\)\
\-\ common\\:\\ 0\\.0038031755305380902\ \(0\)\
\-\ these\\:\\ 0\\.0037820487958466664\ \(0\)\
\-\ more\\:\\ 0\\.003634653587265589\ \(0\)\
\-\ symptoms\\:\\ 0\\.0036218664573097604\ \(0\)\
\-\ physical\\:\\ 0\\.0035654851523490446\ \(0\)\
\-\ chest\\:\\ 0\\.0034774302722066644\ \(0\)\
\-\ 1\\:\\ 0\\.0034580380407478006\ \(0\)\
\-\ tumor\\:\\ 0\\.0033881501728075017\ \(0\)\
\-\ other\\:\\ 0\\.003349725422963348\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0033371077054088773\ \(0\)\
\-\ exam\\:\\ 0\\.003192574727805337\ \(0\)\
\-\ large\\:\\ 0\\.003177793251413401\ \(0\)\
\-\ have\\:\\ 0\\.0031470035346345096\ \(0\)\
\-\ 2\\:\\ 0\\.003129429415834262\ \(0\)\
\-\ but\\:\\ 0\\.0030994954099209824\ \(0\)\
\-\ right\\:\\ 0\\.00306677452078373\ \(0\)\
\-\ and\\:\\ 0\\.0030613776485071166\ \(0\)\
\-\ surgical\\:\\ 0\\.0030547989289990704\ \(0\)\
\-\ female\\:\\ 0\\.0029876875364759073\ \(0\)\
\-\ patient\\:\\ 0\\.0029135779963142447\ \(0\)\
\-\ by\\:\\ 0\\.0024198484749062494\ \(0\)\
\-\ the\\:\\ 0\\.0023511783112861533\ \(0\)\
\-\ of\\:\\ 0\\.002179492872071212\ \(0\)\
\-\ from\\:\\ 0\\.002153802233255463\ \(0\)\
\-\ ct\\:\\ 0\\.0020328293425034743\ \(0\)\
\-\ an\\:\\ 0\\.002009634122933214\ \(0\)\
\-\ \\.\\:\\ 0\\.0019319475427127225\ \(0\)\
\-\ pain\\:\\ 0\\.0017748438223311814\ \(0\)\
\-\ year\\:\\ 0\\.0016260293695117597\ \(0\)\
\-\ no\\:\\ 0\\.0014633403923534046\ \(0\)\
\-\ with\\:\\ 0\\.0013929068582129729\ \(0\)\
